- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01023477
Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)
Preventing Invasive Breast Neoplasia With Chloroquine (PINC) Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Virginia Cancer Specialists, PC
-
Fairfax, Virginia, United States, 22031
- Medical Oncology and Hematology Associates of Northern Virginia
-
Fairfax, Virginia, United States, 22033
- Virginia Surgery Associates
-
Falls Church, Virginia, United States, 22042
- Inova Fairfax Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must have a tissue diagnosis of low, intermediate or high grade ductal carcinoma in situ or ductal carcinoma in situ with microinvasion.
- Patients with ductal carcinoma in situ undergoing either lumpectomy/radiation or mastectomy.
- Patients must be female at least 18 years of age.
- Patients must have a signed tissue acquisition consent and have at minimum, adequate samples of primary fresh tissue or blood available for use in this study.
- No history of a previous invasive cancer in the last five years with the exception of minimally invasive non-melanoma skin cancer.
- Normal liver function based on Liver Function Tests (Total Bilirubin and Asparate transaminase (AST) <1.5 X Upper Limit of Normal).
- Normal White Blood Count (WBC) (3.5-10.8 x 103µL), Platelet count (PLT) (140-400 x 103µL), and Hematocrit (HCT)(37-52%)
- Potassium within the normal range of 3.5-5.3 mEq/L
- Adequate renal sufficiency (serum creatinine <1.5 mg/dL).
- Eastern Cooperative Oncology Group performance status 0-2.
- Are able to swallow and retain oral medication.
- No underlying ocular/retinal pathology.
- No medically documented preexisting auditory damage.
- Subjects should be willing to abstain from use of hormonal therapies (e.g. hormone replacement therapy, oral contraceptive pills, hormone-containing Intra Uterine Device (IUD)s, and E-string) and chronic non-steroidal anti-inflammatory (NSAID) s for the duration of the study (chronic use of NSAID's is defined as a frequency >3 times/week for more than two weeks per year and includes low dose aspirin).
- Subjects with child-bearing potential must agree to use adequate contraception (total abstinence (no sexual intercourse), use of condom with spermicide or sterilization surgery, including tubal ligation (tubes tied) or hysterectomy (removal of the uterus or womb)) prior to study entry and for the duration of study treatment phase. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately.
If a subject is of child-bearing potential (women are considered not of child-bearing potential if they are at least one year postmenopausal and/or surgically sterile), she must have a documented negative serum or urine pregnancy test before starting treatment.
Exclusion Criteria:
- Patients with a prior history of chemotherapy, hormonal ablation therapy and/or radiation therapy.
- History of other invasive cancer in the previous 5 years other than minimally invasive non-melanoma skin cancer.
- Patient desires not to participate in the study.
- Inability to consent.
- Current or recent pregnancy (within 12 months),
- Current use of hormone-containing forms of birth control such as implants (i.e. Norplants, or injectables ( i.e. depo-provera)
- Currently lactating.
- Patients with history of renal or hepatic insufficiency.
- Current diagnosis for depression, including treatment with an Selective Serotonin Reuptake Inhibitor (SSRI).
- History of prior treatment with chloroquine for malaria within past 24 months.
- History of allergic reactions to quinolones or chloroquine.
- Active diagnosis of psoriasis or currently receiving treatment for psoriasis.
- History of porphyria.
- History of known Glucose-6-Phosphate Dehydrogenase (G-6-PD) deficiency.
- Alcoholism or hepatic disease.
- History of epilepsy or seizures in the past 20 years.
- History of deep vein thrombosis or pulmonary embolism.
- History of human immunodeficiency virus (HIV) disease and/or treatment with anti-HIV agents.
- Receiving concurrent treatment with prohibited medications (refer to Table 1 for details on prohibited medications); Examples include: ampicillin, antacids, cimetidine, cyclosporine, kaolin, magnesium trisilicate, coumarin-type anticoagulants, macrolide antibiotics (e.g., clarithromycin, isoniazid, and erythromycin), anti-HIV agents (e.g., ritonavir and delavirdine), antidepressants (e.g. fluoxetine and fluvoxamine), calcium channel blockers (e.g. verapamil and diltiazem), steroids and their modulators (e.g., gestodene, raloxifene, and mifepristone), and several herbal and dietary components (e.g. bergamottin and glabridin).
- Used an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study medication.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Chloroquine Standard Dose (500mg/week)
Patients with ER+ or ER- DCIS regardless of histologic grade will be randomly assigned to receive one month standard dose chloroquine (500 mg/week).
|
Patients will receive chloroquine (500 mg/once a week) for 1 month prior to surgical removal of the DCIS lesion.
Other Names:
Patients diagnosed with DCIS will undergo a breast biopsy prior to the start of study treatment.
This biopsy is entirely voluntary and is not required to remain in the study.
The biopsy will allow researchers to study the tissue for biomarkers and to determine how the DCIS tissue changes during treatment.
Additional samples of the DCIS tissue will be collected at the time of surgery.
Other Names:
|
EXPERIMENTAL: Chloroquine Low Dose (250mg/week)
Patients with ER+ or ER- DCIS regardless of histologic grade will be randomly assigned to receive one month low dose chloroquine (250mg/week).
|
Patients diagnosed with DCIS will undergo a breast biopsy prior to the start of study treatment.
This biopsy is entirely voluntary and is not required to remain in the study.
The biopsy will allow researchers to study the tissue for biomarkers and to determine how the DCIS tissue changes during treatment.
Additional samples of the DCIS tissue will be collected at the time of surgery.
Other Names:
Patients will receive chloroquine (250 mg/once a week) for 1 month prior to surgical removal of the DCIS lesion.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Average Change in the Longest Diameter of the Breast MRI Target Lesion
Time Frame: Immediately preceding study drug treatment and again after treatment prior to surgery. The total time interval was up to 8 weeks
|
One of the primary outcomes of this study was to measure the impact of weekly chloroquine on the amount of DCIS seen on MRI.The tumor response was evaluated by RECIST criteria.
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR The longest diameter of the target lesion or primary area of non-mass enhancement was measured by digital calipers.
For one patient, the longest diameter was difficult to measure due to the presence of a significant post biopsy resolving hematoma at the biopsy site.
Further correlation was made based on the extent of the pre-treatment microcalcifications and post treatment areas of non-mass enhancement.
|
Immediately preceding study drug treatment and again after treatment prior to surgery. The total time interval was up to 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total Number of Treatment-Related Adverse Events
Time Frame: The patients were monitored from the time of diagnosis through 6 months of surgical follow up.
|
One of the outcomes was to ensure the safety of weekly chloroquine.
Patients were followed clinically during the treatment with chloroquine and during their surgery and postoperative period ( including radiation therapy).
Patients were verbally assessed for additional symptoms or concerns.
Patients were also examined by the provider during treatment and follow up visits to the surgeon.
|
The patients were monitored from the time of diagnosis through 6 months of surgical follow up.
|
Effect of Chloroquine on Proliferating Cell Nuclear Antigen (PCNA) Proliferation Index
Time Frame: At the time of breast biopsy and again at time of surgery.
|
We evaluated the effect of therapy on cellular proliferation as measured by the change in proliferating cell nuclear antigen (PCNA) proliferation index.
PCNA , which is elevated during the G1/S phase of the cell cycle, may be used as a marker of cellular proliferation.
The PCNA proliferation index was measured as the number of PCNA positive stained cells in the DCIS lesion/ total number of cells in the lesion.
The change in the PCNA index is equal to the mean PCNA proliferation index pre-treatment minus the mean PCNA proliferation index post-treatment.
|
At the time of breast biopsy and again at time of surgery.
|
Impact of Chloroquine Treatment on the Cell Signaling Kinase Levels in DCIS Lesions.
Time Frame: At the time of surgery
|
The study evaluated the effect of chloroquine treatment on the proteomic signaling profiles of the DCIS lesions. Post treatment surgical specimens were evaluated by immunohistochemical staining to measure cell signaling kinase levels for CD68 and HMGB1. CD68 (Cluster Determinant 68) is a marker of macrophages/monocytes in the breast ducts. and HMGB1 (High Mobility Group Box 1) is involved in oxidative stress-mediated autophagy. HMGB1 is a non-histone DNA binding protein. The number of positive cells were quantified and recorded. . |
At the time of surgery
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Kirsten H Edmiston, MD, FACS, Inova Fairfax Hospital Cancer Center
- Principal Investigator: Priscilla McAuliffe, MD, PhD, Magee-Women's Hospital of UPMC
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Neoplasms, Ductal, Lobular, and Medullary
- Breast Carcinoma In Situ
- Carcinoma in Situ
- Carcinoma
- Carcinoma, Ductal
- Carcinoma, Intraductal, Noninfiltrating
- Physiological Effects of Drugs
- Anti-Infective Agents
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Amebicides
- Filaricides
- Antinematodal Agents
- Anthelmintics
- Chloroquine
- Chloroquine diphosphate
Other Study ID Numbers
- IFHCC 09-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma, Intraductal, Noninfiltrating
-
Laura EssermanMerck Sharp & Dohme LLC; ModernaTX, Inc.RecruitingCarcinoma, Intraductal, NoninfiltratingUnited States
-
Duke UniversityNational Cancer Institute (NCI)CompletedDuctal Carcinoma in SituUnited States
-
Indiana UniversityGlaxoSmithKlineTerminatedDuctal Carcinoma in SituUnited States
-
Ontario Clinical Oncology Group (OCOG)Recruiting
-
Alliance Foundation Trials, LLC.Patient-Centered Outcomes Research Institute; M.D. Anderson Cancer Center; Washington... and other collaboratorsActive, not recruitingDuctal Carcinoma in Situ | DCISUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedBreast CancerUnited States
-
Hologic, Inc.University of Southern CaliforniaCompleted
-
First Hospital of China Medical UniversityJilin Provincial Tumor Hospital; The First Hospital of Jilin University; Second... and other collaboratorsUnknown
-
QuantumLeap Healthcare CollaborativeRecruitingDuctal Carcinoma in SituUnited States
-
Glendale Adventist Medical Center d/b/a Adventist...Helen Rey Breast Cancer Research Foundation; California Oncology Research Institute and other collaboratorsRecruitingDuctal Carcinoma in SituUnited States
Clinical Trials on Chloroquine Standard Dose (500mg/week)
-
The University of Texas Health Science Center,...The Methodist Hospital Research Institute; MedStar National Rehabilitation...RecruitingSpinal Cord InjuriesUnited States
-
University of EdinburghAccord Clinical ResearchNot yet recruitingSystemic Lupus Erythematosus
-
Boehringer IngelheimCompleted
-
Dawonmedax Co., Ltd.RecruitingRecurrent Glioblastoma | Recurrent High-grade Glioma | Recurrent Anaplastic Astrocytoma | Recurrent Anaplastic OligodendrogliomaKorea, Republic of
-
VA Office of Research and DevelopmentNot yet recruitingDiabetic Foot UlcerUnited States
-
BioMarin PharmaceuticalTerminatedDuchenne Muscular DystrophyBelgium, Netherlands, France, United Kingdom, Italy
-
HaEmek Medical Center, IsraelT MAY BIOPHARMA LTD.Terminated
-
National Cancer Institute, EgyptRecruitingHead and Neck CancerEgypt
-
Tata Medical CenterCompletedMalignant Neoplasm of Oropharynx Stage III | Malignant Neoplasm of Larynx Stage III | Malignant Neoplasm of Hypopharynx Stage III | Malignant Neoplasm of Oropharynx Stage IVa | Malignant Neoplasm of Oropharynx Stage IVb | Malignant Neoplasm of Larynx Stage IV | Malignant Neoplasm of Hypopharynx... and other conditionsIndia
-
Fundação de Medicina Tropical Dr. Heitor Vieira...Marcus Vinícius Guimarães de Lacerda; Mayla Gabriela Silva Borba; Wuelton Marcelo... and other collaboratorsCompletedSARS-CoV Infection | Severe Acute Respiratory Syndrome (SARS) PneumoniaBrazil